Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $16.67

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $16.67.

Several equities research analysts have recently commented on the company. Canaccord Genuity Group upped their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st.

Atara Biotherapeutics Price Performance

ATRA stock opened at $10.33 on Friday. The stock has a market capitalization of $59.50 million, a P/E ratio of -0.40 and a beta of 0.55. Atara Biotherapeutics has a 1-year low of $6.50 and a 1-year high of $39.50. The business has a fifty day moving average price of $10.54 and a 200-day moving average price of $9.67.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period last year, the firm posted ($16.50) EPS. As a group, analysts anticipate that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Large investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics in the second quarter worth approximately $79,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics in the 2nd quarter valued at $53,000. Vestal Point Capital LP grew its position in Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after acquiring an additional 12,677 shares during the last quarter. Geode Capital Management LLC increased its stake in Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares during the period. Finally, State Street Corp lifted its position in shares of Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.